Arvinas, Inc. is a Pharmaceuticals company based in the United States that aims to enhance the lives of patients with serious illnesses by developing therapies that target disease-causing proteins. The company utilizes its exclusive Proteolysis-Targeting Chimera (PROTAC) technology to encourage the cell's own ubiquitin-proteasome system to degrade and eliminate harmful proteins. With a medium-risk ESG score of 26.2, Arvinas Inc. is dedicated to sustainability and governance in its operations. Their product candidates include bavdegalutamide, ARV-471, and ARV-766.